MarketInOut Stock Screener Log In | Sign Up
 

Mirum Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Mirum Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,395.87 mln
Float53.80 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-5.11
Highly reliable

1-Year Forecast

153.43
Transformational upside

Relative Strength

31 / 100
Underperforming

Pre-Tax Margin

-139%
Severely loss-making

ROE

-393
Deeply negative

Business Description

Mirum Pharmaceuticals is a Foster City, California-based company founded in 2018 that develops and sells treatments for rare liver and metabolic diseases. Its approved products include LIVMARLI, a drug for severe itching caused by Alagille syndrome, along with Cholbam and Chenodal, which address bile acid disorders and gallstones respectively. The company also has several treatments in clinical trials targeting liver disease, chronic HDV infection, and fragile X syndrome. Mirum works with a number of partners, including Pfizer, Novartis, and Sanofi, to support its research and commercial operations.

Key Fundamentals

EPS-14.10
ROE-393
RPS11.02
ROIC-25.26
ROA-100
Interest Cover-8.01
EBITDA, mln-818
EV / EBITDA-7.06
EV / EBIT-6.84
Revenue, mln618
EV / Revenue9.34

Quote Details

Last 80.39
Change -2.71 (-3.26%)
Open 82.39
Volume 788,213
Turnover 63,364,444
Average Volume 818,995

Financial Ratios

Pre-Tax Profit Margin-139
Current Ratio2.86
Price / Sales8.04

Financial Strength

Altman Z-Score-0.41
Piotroski F-Score 3 / 9
Beneish M-Score-5.11
1-Year Target Price153.43
Short Ratio9.65
Short % of Float13.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.31% 62 / 100   
1 Month -10.04% 29 / 100   
2 Months -31.07% 16 / 100   
6 Months -12.13% 32 / 100   
1 Year 15.5% 75 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog